Results 91 to 100 of about 184,118 (312)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Medication Errors in Pediatrics

Pediatrics and Neonatology, 2013
Chih-Jung Chen
doaj   +1 more source

Evaluation of the frequency and type of medication prescribing errors in the NICU of hospitals in Yazd

حیات, 2016
Background & Aim: Medication errors are one of the most common medical errors and these errors have a double importance in neonatal intensive care unit.
Naiire Salmani, Shirin Hasanvand
doaj  

Prevalence of medication errors and its related factors in Iranian nurses: an updated systematic review and meta-analysis

BMC Nursing
Background Nurses may make medication errors during the implementation of therapeutic interventions, which initially threaten the patient’s health and safety and prolong their hospital stay.
Hadis Fathizadeh, Samaneh-Sadat Mousavi, Zahra Gharibi, Hamidreza Rezaeipour, Abdol-Rahim Biojmajd   +4 more
doaj   +1 more source

Incidence and prevalence of intravenous medication errors in the UK: a systematic review [PDF]

, 2018
Adam Sutherland, Michela Canobbio, J. G. R. Clarke, Michelle Randall, Tom Skelland, Emma Weston   +5 more
openalex   +1 more source

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

Molecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués, Aracele Martinez‐Mendez, John Crown, Alex Eustace   +3 more
wiley   +1 more source

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

Molecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice, Jose I. Lopez, Aitziber Ugalde‐Olano, Maite Zufiaurre, Ianire Astobiza, Natalia Martin‐Martin, Laura Bozal‐Basterra, Saioa Garcia‐Longarte, Amaia Zabala‐Letona, Sofia Rey, Aida Santos‐Martin, Miguel Unda, Ana Loizaga‐Iriarte, Mariona Graupera, Paolo Nuciforo, Arkaitz Carracedo, Isabel Mendizabal   +16 more
wiley   +1 more source

IDENTIFICACIÓN Y ANÁLISIS DE LOS ERRORES DE MEDICACIÓN EN SEIS HOSPITALES BRASILEÑOS

Ciencia y Enfermería
Esta investigación identificó, a través del método de observación directa, los errores de medicación ocurridos en unidades de clínica médica de seis hospitales brasileños.
Silvia Helena de Bortoli Cassiani, Aline Aparecida Silvia Monzani, Ana Elisa Bauer De Camargo Silva, Flávio Trevisani Fakih, Simone Perufo Opitz, Thalyta Cardoso Alux Teixeira   +5 more
doaj   +1 more source

Medication Errors: Will Punitive Measures Help to Decrease the Occurrence? A Case Study [PDF]

, 2013
Irene J. Su
openalex   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source